We are live on ! Find out more
TPC

Takeda Pharmaceutical Company Portfolio holdings

AUM $16.4M
1-Year Est. Return 195.92%
This Fund
S&P 500
This Quarter Est. Return
+19.92%
1 Year Est. Return
+195.92%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$327M
AUM Growth
–
Cap. Flow
+$284M
Cap. Flow %
86.87%
Top 10 Hldgs %
99.54%
Holding
14
New
14
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
HLVX
HilleVax
HLVX
+$89.3M
2
DNLI icon
Denali Therapeutics
DNLI
+$83.5M
3
PHAT icon
Phathom Pharmaceuticals
PHAT
+$64.3M
4
OVID icon
Ovid Therapeutics
OVID
+$25.7M
5
WVE icon
Wave Life Sciences
WVE
+$7.2M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HLVX
1
DELISTED
HilleVax
HLVX
$108M 32.95%
+6,724,000
New +$89.3M
DNLI icon
2
Denali Therapeutics
DNLI
$3.84B
$86.9M 26.55%
+4,214,559
New +$83.5M
PHAT icon
3
Phathom Pharmaceuticals
PHAT
$666M
$77.4M 23.62%
+7,459,286
New +$64.3M
OVID icon
4
Ovid Therapeutics
OVID
$489M
$24.3M 7.41%
+7,531,996
New +$25.7M
STTK icon
5
Shattuck Labs
STTK
$704M
$14.9M 4.55%
+2,090,858
New +$5.7M
WVE icon
6
Wave Life Sciences
WVE
$1.17B
$7.57M 2.31%
+1,346,892
New +$7.2M
AMWL icon
7
American Well
AMWL
$221M
$2.32M 0.71%
+77,733
New +$1.91M
TSBX
8
DELISTED
Turnstone Biologics
TSBX
$2.28M 0.7%
+895,824
New +$2.34M
EQ icon
9
Equillium
EQ
$138M
$1.31M 0.4%
+1,824,977
New +$1.08M
RANI icon
10
Rani Therapeutics
RANI
$87.7M
$1.12M 0.34%
+338,679
New +$783K
XLO icon
11
Xilio Therapeutics
XLO
$59.9M
$811K 0.25%
+105,366
New +$2.08M
AKLI
12
DELISTED
Akili Inc
AKLI
$360K 0.11%
+738,819
New +$341K
JBIO
13
Jade Biosciences
JBIO
$1.32B
$307K 0.09%
+388
New +$198K
LAB icon
14
Standard BioTools
LAB
$307M
$36.5K 0.01%
+16,515
New +$35.3K

Similar funds

KL
KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return
LM
Lasry Marc $15.1M AUM 10.39% 1-Year Est. Return
DADR
Dynamo Administracao de Recursos Rio De Janeiro, Brazil $18.5M AUM 37.41% 1-Year Est. Return
AVM
Avalon Ventures Management La Jolla, California $14.2M AUM 9.35% 1-Year Est. Return
RCMU
Rokos Capital Management (US) New York $14.2M AUM
PM
Pharo Management New York $18.7M AUM
SHM
Sagard Holdings Management Toronto, Ontario, Canada $20M AUM
SI
SQN Investors Menlo Park, California $12.8M AUM

Takeda Pharmaceutical Company's Q4 2023 Portfolio in Review

Q4 2023 is the first quarter with a 13F filing on record for Takeda Pharmaceutical Company, which disclosed 14 positions worth $327M. Its ten largest holdings account for 100% of the portfolio.

Its largest position is HilleVax: 6,724,000 shares worth $108M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets.

  • Takeda Pharmaceutical Company's largest Q4 2023 buy was HilleVax: 6,724,000 shares worth $108M.
  • Takeda Pharmaceutical Company's ten largest holdings make up 100% of its $327M portfolio in Q4 2023.
  • Takeda Pharmaceutical Company disclosed 14 positions in Q4 2023, its first 13F filing on record.

Based on Takeda Pharmaceutical Company's 13F filing for Q4 2023, filed 13 Feb 2025.